| Predicted Trait | |
| Reported Trait | Prostate cancer |
| Mapped Trait(s) | prostate carcinoma (EFO_0001663) |
| Score Construction | |
| PGS Name | PrCa66 |
| Variants | |
| Original Genome Build | GRCh38 |
| Number of Variants | 66 |
| Development Method | |
| Name | Known susceptibility loci (genome-wide significant SNPs) |
| Parameters | P-value < 5E-8, top SNP |
| PGS Source | |
| PGS Catalog Publication (PGP) ID | PGP000031 |
| Citation (link to publication) | Pashayan N et al. Br J Cancer (2015) |
| Study Identifiers | Sample Numbers | Sample Ancestry |
|---|---|---|
| GWAS Catalog: GCST001942 EuropePMC: 23535732 |
22,548 individuals | European |
| GWAS Catalog: GCST001148 EuropePMC: 21743467 |
13,560 individuals | European |
| GWAS Catalog: GCST000153 EuropePMC: 18264098 |
23,226 individuals | European |
| GWAS Catalog: GCST000488 EuropePMC: 19767753 |
3,748 individuals | European |
| GWAS Catalog: GCST000750 EuropePMC: 20676098 |
4,969 individuals | East Asian |
| GWAS Catalog: GCST001147 EuropePMC: 21743057 |
7,240 individuals | European |
| GWAS Catalog: GCST000152 EuropePMC: 18264097 |
3,748 individuals | European |
| GWAS Catalog: GCST000489 EuropePMC: 19767754 |
37,350 individuals | European |
| GWAS Catalog: GCST000154 EuropePMC: 18264096 |
2,329 individuals | European |
| GWAS Catalog: GCST000017 EuropePMC: 17401363 |
2,329 individuals | European |
| GWAS Catalog: GCST001702 EuropePMC: 23023329 |
2,425 individuals | East Asian |
| GWAS Catalog: GCST000128 EuropePMC: 18073375 |
2,834 individuals | European |
| GWAS Catalog: GCST001714 EuropePMC: 23065704 |
22,548 individuals | European |
| GWAS Catalog: GCST000019 EuropePMC: 17401366 |
4,517 individuals | European |
Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.
|
PGS Performance Metric ID (PPM ID) |
PGS Sample Set ID (PSS ID) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
PGS Classification Metrics | Other Metrics | Covariates Included in the Model | PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|
| PPM000104 | PSS000068 | PGP000031 Pashayan N et al. (2015) |
Reported Trait: Elevated serum prostate-specific antigen (PSA) levels | — | — | OR (per 1-point increase in PRS): 1.23[1.1, 1.37] | cancer stage, Gleason score | — |
| PPM000105 | PSS000069 | PGP000032 Pashayan N et al. (2015) Ext. |
Reported Trait: aggressive prostate cancer (Gleason score ⩾7) | — | — | OR (above vs. below 50th percentile of PRS): 1.56[1.15, 2.1] | — | — |
|
PGS Sample Set ID (PSS ID) |
Detailed Phenotype Description | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS000068 | Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml. | — | [ ,
100.0 % Male samples |
Range = [50.0, 60.0] years | European | — | UKGPCS | — |
| PSS000069 | Prostate cancer was classified as localised disease with tumour-node-metastasis (TNM) stage T1-2 N0 M0; and advanced disease (regional-distant) with stage T3 and above or any T N1 M1; as non-aggressive tumour, Gleason score <7, and aggressive tumour, Gleason score ⩾7. | Median = 13.0 years | [ ,
100.0 % Male samples |
Range = [55.0, 71.0] years | European (Finnish) |
— | ERSPC | — |
| PSS000068 | Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml. | — | [ ,
100.0 % Male samples |
Range = [50.0, 69.0] years | European | — | ProtecT | — |
| PSS000068 | Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml. | — | [ ,
100.0 % Male samples |
Range = [50.0, 69.0] years | European | — | SEARCH | — |